Anatomical main group
D – DERMATIKA
27Decisions
32Patient groups
Added benefit by patient group
- Considerable3
- Minor2
- Non-quantifiable6
- Not proven21
Subgroups
- D02 EMOLLIENTIA UND HAUTSCHUTZMITTEL 1 decision
- D03 ZUBEREITUNGEN ZUR BEHANDLUNG VON WUNDEN UND GESCHWÜREN 3 decisions
- D05 ANTIPSORIATIKA 1 decision
- D06 ANTIBIOTIKA UND CHEMOTHERAPEUTIKA ZUR DERMATOLOGISCHEN ANWENDUNG 1 decision
- D10 AKNEMITTEL 1 decision
- D11 ANDERE DERMATIKA 20 decisions
Decisions, newest first
- 2026-02-19VyjuvekBeremagen geperpavecNon-quantifiable
- 2025-08-07NemluvioNemolizumabNot proven
- 2025-08-07NemluvioNemolizumabNot proven
- 2025-05-15DupixentDupilumabNot proven
- 2025-04-03AnzupgoDelgocitinibNot proven: 2 of 2 patient groups
- 2025-02-06DupixentDupilumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-10-17CibinqoAbrocitinibNot proven
- 2024-06-06EbglyssLebrikizumabNot proven
- 2023-10-05DupixentDupilumabNon-quantifiable
- 2023-09-21DupixentDupilumabNot proven
- 2023-09-21DupixentDupilumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-05-12AdtralzaTralokinumabNot proven
- 2023-02-16FilsuvezBirkenrindenextraktMinor
- 2023-01-19AxhidroxGlycopyrroniumNot proven
- 2022-10-06DupixentDupilumabNot proven
- 2022-07-07CibinqoAbrocitinibConsiderable
- 2022-02-17KlisyriTirbanibulinNot proven
- 2022-01-06AdtralzaTralokinumabNot proven
- 2021-07-01ScenesseAfamelanotidNon-quantifiable
- 2021-07-01DupixentDupilumabNon-quantifiable
- 2021-02-04SelgamisTrifarotenNot proven
- 2020-05-14DupixentDupilumabConsiderable
- 2020-02-20DupixentDupilumabNon-quantifiable
- 2020-02-20DupixentDupilumabNot proven: 2 of 2 patient groups
- 2018-05-17DupixentDupilumabConsiderable
- 2018-03-16SkilarenceDimethylfumaratNot proven: 2 of 2 patient groups
- 2014-11-20BioBaglebende Larven von Lucilia sericataNot proven
Data status: 2026-10-29